BioNTech co-founder Ugur Sahin says the frontrunner COVID-19 vaccine his German firm is developing with Pfizer could be rolled out before the year is over in the United States or Europe.
“We are working at full speed,” he tells AFP in a Zoom interview, confirming that the companies planned to apply for emergency use authorization of their jab in the US on Friday, while European regulators will receive another batch of data “next week.”
“There is a chance that we can receive approval from the US or Europe or both regions this year still,” says Sahin, 55, who is also BioNTech’s chief executive.
“We may even start delivering the vaccine in December,” he added, “if everyone works together very closely.”
The BioNTech/Pfizer shot and another one being developed by US firm Moderna have taken the lead in the global chase for a vaccine, after large-scale trial data this month showed that their jabs were around 95 percent effective against COVID-19.
Uğur Şahin (Kuebi; Armin Kübelbeck; Wikipedia)
The twin breakthroughs have lifted hopes for an end to a pandemic that has infected more than 56 million people and caused more than 1.3 million deaths worldwide since the virus first emerged in China late last year.
The US, the European Union and a slew of other nations, including Israel, have already placed orders for hundreds of millions of doses of the top vaccine candidates in development.
Health workers, carers and people considered at high risk for severe COVID-19 are set to be first in line for the jabs.
— AFP
We can't do this work alone.
The war with Iran has been draining for all of us in Israel. But when I heard about a high casualty incident – ballistic missile impacts in Arad and Dimona that left nearly 200 people wounded – I drank a cup of coffee, packed a bag, and headed south.
There, I spoke with Shilgit, the head of an after-school program for underprivileged youth. Standing outside her destroyed center, Shilgit said it was a miracle that no children were hurt and spoke about the community coming together in the hours since.
As a Times of Israel reporter, I’m committed to telling stories of resilience like Shilgit’s. But my colleagues and I can't do this alone. If you value work like this,please consider joining our reader support group, The Times of Israel Community. Your financial support is essential to keep real human reporting like this going.
We’re really pleased that you’ve read X Times of Israel articles in the past month.
That’s why we started the Times of Israel - to provide discerning readers like you with must-read coverage of Israel and the Jewish world.
So now we have a request. Unlike other news outlets, we haven’t put up a paywall. But as the journalism we do is costly, we invite readers for whom The Times of Israel has become important to help support our work by joining The Times of Israel Community.
For as little as $6 a month you can help support our quality journalism while enjoying The Times of Israel AD-FREE, as well as accessing exclusive content available only to Times of Israel Community members.
Thank you, David Horovitz, Founding Editor of The Times of Israel
From the Liveblog of
Thursday, November 19, 2020
